申请人:——
公开号:US05073641A1
公开(公告)日:1991-12-17
##STR1## Novel ester derivatives of carboxylic acid medicaments of formula (I), wherein R--COO--represents the acyloxy residue of a carboxylic acid drug or medicament, n is an integrer from 1 to 3, and R.sub.1 and R.sub.2 are the same or different and are selected from a group consisting of an alkyl, an alkenyl, an aryl, an aralkyl, a cycloalkyl and which group may be unsubstituted or substituted, or R.sub.1 and R.sub.2 together with the N forms a 4-, 5-, 6- or 7-membered heterocyclic ring, which in addition to the nitrogen atom may contain one or two further heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and which heterocyclic group may be substituted. These compounds are highly biolabile prodrug forms of the corresponding carboxylic acid compounds and are highly susceptible to undergoing enzymatic hydrolysis in vivo whereas they are highly stable in aqueous solution. The novel derivatives are less irritating to mucosa than the parent carboxylic acids and may provide an improved bio-availability of the drugs.
化学药物的新酯衍生物,其中R--COO--代表羧酸药物或药剂的酰氧基团,n为1至3的整数,R.sub.1和R.sub.2相同或不同,选自烷基、烯基、芳基、芳基烷基、环烷基的一组,该组可能未取代或取代,或R.sub.1和R.sub.2与N一起形成4、5、6或7元杂环,除氮原子外,还可能含有来自氮、氧和硫的一到两个进一步的杂原子,该杂环基可能被取代。这些化合物是相应羧酸化合物的高度生物可降解的前药形式,极易在体内经受酶水解,而在水溶液中则非常稳定。这些新的衍生物对粘膜的刺激性较原始羧酸小,并可能提高药物的生物利用度。